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Letters  to  the  Editor
Emergence of OXA-72-producing Acinetobacter
pittii  clinical isolates
Sir,
The  genus Acinetobacter comprises 47 characterised genomic
species, among which species belonging to the Acinetobacter
calcoaceticus–Acinetobacter baumannii complex are the most clin-
ically relevant. Within this complex, A. baumannii, Acinetobacter
nosocomialis (formerly genomic species 13TU) and Acinetobac-
ter pittii (formerly genomic species 3) are frequently associated
with hospital-acquired infections [1]. Carbapenem resistance is
being increasingly reported in Acinetobacter spp. isolates and this
resistance trait is often related to the production of acquired
carbapenem-hydrolysing class D -lactamases (CHDLs) that are
disseminating worldwide [2]. Five groups of acquired CHDLs have
been identiﬁed to date in  A. baumannii, namely OXA-23, OXA-
24/-40, OXA-58, OXA-143 and OXA-235 [2]. OXA-72 is  a  point
mutant of OXA-40 that was ﬁrst described in  carbapenem-resistant
A. baumannii clinical isolates in  China [2]. It was then reported in
Colombia from a clinical isolate (A.  pittii 2688), which has been used
here as a reference strain [3].
This study was initiated by  the isolation of three imipenem-
non-susceptible Acinetobacter spp. isolates recovered in  three
hospitals in France in  2011–2013. Isolate RA1 was from the spu-
tum of a patient hospitalised in November 2011, isolate RA2 was
from pus of an 84-year-old patient in  December 2011, and iso-
late RA3 was  recovered after rectal screening of a 56-year-old
patient in May  2013. These isolates were resistant to  penicillins
and penicillin–inhibitor combinations and were of intermediate
susceptibility to carbapenems according to  European Commit-
tee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints
(http://www.eucast.org/clinical breakpoints/). By contrast, they
remained susceptible to ceftazidime and cefepime as well as
to amikacin, rifampicin, colistin, ﬂuoroquinolones, tetracycline
and tigecycline according to  the EUCAST guidelines. The isolates
were identiﬁed using the API32GN system (bioMérieux, Marcy
l’Étoile, France), partial sequencing of their 16S rDNA genes and
matrix-assisted laser desorption/ionisation time-of-ﬂight mass
(MALDI-TOF) analysis. Identiﬁcation results showed that the three
Acinetobacter spp. strains belonged to the A. pittii species.
Since the resistance phenotype to  -lactams suggested the pro-
duction of a CHDL, corresponding genes were searched by PCR as
described previously [2]. Interestingly, PCR followed by sequencing
analysis identiﬁed the blaOXA-72 gene in the three isolates.
To determine the genetic location of the blaOXA-72 gene, transfer
of the ticarcillin resistance marker into A. baumannii BM4547 was
attempted by liquid mating-out assays at 37 ◦C and by electrotrans-
formation of a plasmid DNA suspension extracted from the three
clinical isolates and the reference strain (A.  pittii 2688). Conjugation
remained unsuccessful; nevertheless, transformants were obtained
for the three clinical isolates and the reference strain, revealing
Fig. 1. Results of DiversiLab (bioMérieux, La  Balme-les-Grottes, France) analysis.
The  horizontal similarity line showed the cut-off to  separate different clones.
that blaOXA-72 was plasmid-located in all isolates. Plasmid analy-
sis using the A. baumannii PCR-based replicon typing (AB-PBRT)
scheme revealed that all French isolates possessed a plasmid of  ca.
20 kb in size belonging to  the GR12 family plasmid, as deﬁned previ-
ously [4], whereas the Colombian isolate was negative for this PCR.
Shotgun DNA cloning was  then performed to identify the genetic
structure surrounding the blaOXA-72 gene. It  revealed very simi-
lar structures to those identiﬁed on the GR12 plasmid-type and
blaOXA-72-positive plasmid pMMD  identiﬁed in a  clinical isolate of
A. baumannii from Spain [5]. Altogether, these data indicated that
these three plasmids, although originating from different strains,
were likely the same.
Genotypic  comparison was performed by DiversiLab following
the manufacturer’s instructions (bioMérieux, La Balme-les-Grottes,
France). The clinical isolate of OXA-72-producing A. pittii 2688 from
Colombia was  used as a  reference strain for comparison [3]. Geno-
typing analysis showed that the four isolates corresponded to  three
distinct clones (A–C) (Fig. 1), with the Colombian isolate being dis-
tantly related to the French isolates. Two  isolates, namely RA2 and
RA3, were closely related. These two  isolates have been recovered,
respectively, in northern and southern suburb hospitals of  Paris in
2011 and 2013. The remaining isolate recovered in another city in
France was  not related to  the others.
This study constitutes the very ﬁrst report of OXA-72-producing
A. pittii in Europe following the initial identiﬁcation of an OXA-72-
producing A. pittii in Colombia. The fact that the same clone has
been recovered in two  different hospital settings 2 years apart likely
indicated that this clone might be more widespread than expected.
The difﬁculties in identifying A. pittii species might underestimate
their clinical relevance, in  accordance with a  series of recent studies
showing that non-baumannii Acinetobacter spp. were more clini-
cally signiﬁcant than expected.
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